Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell

MT Newswires Live
08/13

Parabilis Medicines (PBLS) reported a Q2 loss Thursday $2.32 per diluted share, compared a loss of $22.28 a year earlier.

Analysts from FactSet expected a loss of $0.36.

Collaboration revenue for the quarter ended June 30 was $148,000. The company did not report any revenue a year ago.

As of June 30, the company has cash, cash equivalents and marketable securities of $1.1 billion, which it said are expected to fund its operations into 2030.

Shares of the company were up over 6% in Thursday's premarket activity.

Price: 39.99, Change: +2.58, Percent Change: +6.90

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10